WO2016203436A1 - Dispersions amorphes et solides amorphes de lesinurad et leur préparation - Google Patents

Dispersions amorphes et solides amorphes de lesinurad et leur préparation Download PDF

Info

Publication number
WO2016203436A1
WO2016203436A1 PCT/IB2016/053605 IB2016053605W WO2016203436A1 WO 2016203436 A1 WO2016203436 A1 WO 2016203436A1 IB 2016053605 W IB2016053605 W IB 2016053605W WO 2016203436 A1 WO2016203436 A1 WO 2016203436A1
Authority
WO
WIPO (PCT)
Prior art keywords
lesinurad
amorphous
solid dispersion
mixture
solvent
Prior art date
Application number
PCT/IB2016/053605
Other languages
English (en)
Inventor
Bhaskar KANDAGATLA
Srinivas ORUGANTI
Subbareddy Peddireddy
Ajit Prabhakar WALKE
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of WO2016203436A1 publication Critical patent/WO2016203436A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Definitions

  • Present application relates to process for preparation of amorphous form of lesinurad. Another aspect of the present invention is directed to amorphous lesinurad characterized by X-ray diffractogram. Another aspect of the present application is directed to amorphous solid dispersion of lesinurad. Still another aspect of the present application relates to process for the preparation of amorphous solid dispersion of lesinurad.
  • Lesinurad is a selective uric acid re-absorption inhibitor (SURI). Lesinurad or its salt is used for reducing serum uric acid level and for the treatment of gout and hyperurecemia. Lesinurad is chemically known as 2-(5-bromo-4-(4-cyclopropyl naphthalen-1 -yl)-4H-1 ,2,4-triazol-3-ylthio)acetic acid and has following structural formula (I):
  • US8546436B2 discloses crystalline Forms I and 2 of lesinurad and their processes for preparation. Similarly, US8524754B2 discloses crystalline forms A, B, B', C, D and E of lesinurad sodium and their processes for preparation.
  • polymorphism refers to the ability of a substance to exist as two or more crystalline phases that have different spatial arrangements and/or conformations of molecules in their crystal lattices.
  • polymorphs refer to different crystalline forms of the same pure substance in which the molecules have different spatial arrangements of the molecules, atoms, and/or ions forming the crystal. Different polymorphs may have different physical properties such as melting points, solubilities, X-ray diffraction patterns, etc.
  • the variation in solid forms may appreciably influence the pharmaceutical properties, such as bioavailability, handling properties, dissolution rate, and stability, and in turn such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorphic form.
  • pharmaceutical properties such as bioavailability, handling properties, dissolution rate, and stability
  • regulatory authorities require drug manufacturing companies to put efforts into identifying all polymorphic forms, e.g., crystalline, amorphous, solvates, stable dispersions with a pharmaceutically acceptable carriers, etc., of new drug substances.
  • amorphous form and amorphous solid dispersion form of a drug may exhibit a higher bioavailability than its crystalline counterparts, which leads to the selection of the amorphous or its solid dispersion form as the final drug substance for pharmaceutical dosage form development.
  • the solubility of crystalline form is lower than its amorphous or amorphous solid dispersion in some instances, particularly aqueous solubility, which may result in the difference in their in-vivo bioavailability. Therefore, it is desirable to have amorphous or amorphous solid dispersion form of a drug to meet the needs of drug development and also a reproducible process for their preparation. Hence, it is desirable to provide amorphous or amorphous solid dispersion of lesinurad.
  • the present application relates to amorphous form of lesinurad which may be characterized by a PXRD pattern substantially as illustrated in figure-1 .
  • the present application relates to process for preparing amorphous form of lesinurad comprising:
  • the present application relates to process for preparing amorphous form of lesinurad comprising:
  • the present application relates to amorphous solid dispersion of lesinurad together with at least one pharmaceutically acceptable excipient.
  • the present application relates to amorphous solid dispersion of lesinurad together with HPMC which may be characterized by X-ray diffractogram as shown in figure-3.
  • the present application relates to amorphous solid dispersion of lesinurad together with PVP K-30.
  • the present application relates to process for preparing amorphous solid dispersion of lesinurad comprising: a) dissolving lesinurad and one or more pharmaceutically acceptable excipients in a suitable solvent or mixture thereof;
  • the present application relates to process for preparing amorphous solid dispersion of lesinurad comprising blending of lesinurad with one or more pharmaceutically acceptable excipients.
  • the present application provides pharmaceutical formulations comprising amorphous form of lesinurad, together with one or more pharmaceutically acceptable carrier, diluents and excipients.
  • the present application provides pharmaceutical composition comprising amorphous solid dispersion of lesinurad with a pharmaceutically acceptable excipient, together with one or more pharmaceutically acceptable excipients.
  • Figure 1 is an illustration of a PXRD pattern of amorphous form of lesinurad obtained by the example 1 .
  • Figure 2 is an illustration of a PXRD pattern of amorphous form of lesinurad obtained by the example 2.
  • Figure 3 is an illustration of a PXRD pattern of amorphous form of solid dispersion of lesinurad obtained by the example 5.
  • Figure 4 is an illustration of a PXRD pattern of amorphous form of solid dispersion of lesinurad obtained by the example 7.
  • Figure 5 is an illustration of a PXRD pattern of amorphous form of solid dispersion of lesinurad obtained by the example 8.
  • Figure 6 is an illustration of a PXRD pattern of amorphous form of solid dispersion of lesinurad obtained by the example 9.
  • Figure 7 is an illustration of a PXRD pattern of amorphous form of solid dispersion of lesinurad obtained by the example 10.
  • the present application relates to amorphous form of lesinurad which may be characterized by a PXRD pattern substantially as illustrated in Figure 1 .
  • the present application relates to process for preparing amorphous form of lesinurad comprising:
  • Any crystalline form or amorphous form of lesinurad sodium or mixture thereof may be used as starting material for preparing amorphous form of lesinurad.
  • Lesinurad sodium may be prepared by methods known in the art.
  • Suitable solvents of step a) for dissolving lesinurad sodium include, but are not limited to water, dimethylformamide; dimethylacetamide; dimethyl sulphoxide; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone; ethers such as tetrahydrofuran, dioxane; esters such as ethyl acetate, isopropyl acetate; halogenated hydrocarbons such as chloroform, dichloromethane; alcohols such as methanol, ethanol, propanol, isopropanol; and mixtures thereof.
  • Suitable acid of step c) include, but are not limited to hydrochloric acid, sulfuric acid, nitric acid, acetic acid, hydrobromic acid and the like.
  • the isolation of the crude compound after the step (c) may be carried out by solvent extraction.
  • suitable solvents that may be used for extraction include, but are not limited to, ethers such as tetrahydrofuran, dioxane; esters such as ethyl acetate, isopropyl acetate; aromatic hydrocarbons such as toluene, xylene, ethylbenzene; halogenated hydrocarbons such as chloroform, dichloromethane and the like.
  • Suitable techniques that may be used for the removal of solvent include but are not limited to rotational distillation using a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • ATFD agitated thin film drying
  • freeze drying lyophilization
  • the isolation and purification can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, centrifugation, extraction, acid-base treatment, conventional isolation and refining means such as concentration, concentration under reduced pressure, solvent-extraction, crystallization, phase-transfer chromatography, column chromatography, or by a combination of these procedures.
  • suitable separation or purification procedure such as, for example, filtration, centrifugation, extraction, acid-base treatment, conventional isolation and refining means such as concentration, concentration under reduced pressure, solvent-extraction, crystallization, phase-transfer chromatography, column chromatography, or by a combination of these procedures.
  • the resulting solid may be collected by using techniques such as by scraping, or by shaking the container or other techniques specific to the equipment used.
  • the isolated solid may be optionally further dried to afford amorphous form of lesinurad.
  • Drying in the embodiments of the present invention may be suitably carried out by using any of an air tray dryer, vacuum tray dryer, fluidized bed dryer, spin flash dryer, flash dryer, and the like.
  • the drying may be carried out at atmospheric pressure or above, or under reduced pressures, specifically at temperatures less than about 80 °C and more specifically less than about 60 °C.
  • the drying may be carried out for any time period required for obtaining a desired product quality, such as from about 30 minutes to about 24 hours, or longer.
  • the steps of the above embodiment may be performed at a temperature of about 0°C to about the boiling point of the solvent.
  • lesinurad sodium may be dissolved in a suitable solvent at a temperature of about 0°C to about 70°C.
  • the dried product may optionally be subjected to a particle size reduction procedure to produce desired particle sizes and distributions. Milling or micronization may be performed before drying, or after the completion of drying of the product.
  • Equipment that may be used for particle size reduction includes but not limited to ball mill, roller mill, hammer mill, and jet mill.
  • the amorphous form of lesinurad of the present invention is substantially free of any crystalline form of lesinurad.
  • Amorphous form of lesinurad of the present invention does not contain more than about 10 % of any crystalline form of lesinurad.
  • amorphous form of lesinurad does not contain more than about 5 % of any crystalline form of lesinurad.
  • amorphous form of lesinurad does not contain more than about 3 % of any crystalline form of lesinurad.
  • amorphous form of lesinurad does not contain more than about 1 % of any crystalline form of lesinurad.
  • Fig. 1 illustrate PXRD pattern of amorphous lesinurad obtained by process of example 1 .
  • the amorphous form of lesinurad is stable and has excellent physico-chemical properties.
  • the amorphous form of lesinurad of the present application may be easily formulated into a pharmaceutical composition along with suitable pharmaceutically acceptable excipients.
  • the amorphous form of lesinurad obtained in the present invention may be converted to either crystalline or amorphous form of lesinurad sodium by following the methods known in the art.
  • the present application relates to process for preparing amorphous form of lesinurad comprising:
  • Suitable solvents of step a) for dissolving lesinurad include, but are not limited to ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone; alcohols such as methanol, ethanol, propanol, isopropanol; halogenated hydrocarbons such as chloroform, dichloromethane; and mixtures thereof.
  • Suitable techniques that may be used for the removal of solvent in step c) include but are not limited to rotational distillation using a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • the isolation and purification can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, centrifugation, extraction, acid-base treatment, conventional isolation and refining means such as concentration, concentration under reduced pressure, solvent-extraction, crystallization, phase-transfer chromatography, column chromatography, or by a combination of these procedures.
  • the resulting solid may be collected by using techniques such as by scraping, or by shaking the container or other techniques specific to the equipment used.
  • the isolated solid may be optionally further dried to afford amorphous form of lesinurad.
  • the steps of the above embodiment may be performed at a temperature of about 0°C to about the boiling point of the solvent. Specifically, lesinurad may be dissolved in a suitable solvent at a temperature of about 0°C to about 1 10°C.
  • the present application relates to amorphous solid dispersion of lesinurad together with at least one pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient may include but not limited to methyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl cellulose, polysaccharides, heteropolysaccharides (pectins), poloxamers, poloxamines, ethylene vinyl acetates, polyethylene glycols, dextrans, polyvinylalcohols, propylene glycols, polyvinylacetates, phosphatidylcholines (lecithins), miglyols, polylactic acid, polyhydroxybutyric acid, polyvinylpyrrolidones (PVP), copovidone, methacrylic acid, silicon dioxide, mixtures of two or more thereof, copolymers thereof and derivatives thereof.
  • PVP polyvinylpyrrolidones
  • the present application relates to amorphous solid dispersion of Lesinurad with polyvinylpyrrolidones (PVP). More specifically, the present application relates to amorphous solid dispersion of lesinurad with PVP K-30 or HPMC.
  • PVP polyvinylpyrrolidones
  • the weight/weight ratio of lesinurad and pharmaceutically acceptable excipient in amorphous solid dispersion may be about 5:95, or about 10:90, or about 15:85, or about 20:80, or about 25:75, or about 30:70, or about 35:65, or about 40:60, or about 45:55, or about 50:50 and vice versa.
  • the present application relates to amorphous solid dispersion of lesinurad together with HPMC which may be characterized by X-ray diffractogram as shown in figure-3.
  • the present application relates to amorphous solid dispersion of lesinurad together with PVP K-30.
  • the present application relates to process for preparing amorphous solid dispersion of lesinurad comprising:
  • Suitable solvents of step a) for dissolving lesinurad include, but are not limited to water, dimethylformamide; dimethylacetamide; dimethyl sulphoxide; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone; alcohols such as methanol, ethanol, propanol, isopropanol; halogenated hydrocarbons such as chloroform, dichloromethane; ethers such as tetrahydrofuran, dioxane; esters such as ethyl acetate, isopropyl acetate; and mixtures thereof.
  • the pharmaceutically acceptable excipient of step a) may include but not limited to methyl cellulose, ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl cellulose, polysaccharides, heteropolysaccharides (pectins), poloxamers, poloxamines, ethylene vinyl acetates, polyethylene glycols, dextrans, polyvinylalcohols, propylene glycols, polyvinylacetates, phosphatidylcholines (lecithins), miglyols, polylactic acid, polyhydroxybutyric acid, polyvinylpyrrolidones (PVP), copovidone, methacrylic acid, silicon dioxide, mixtures of two or more thereof, copolymers thereof and derivatives thereof.
  • PVP polyvinylpyrrolidones
  • the present application relates to amorphous solid dispersion of Lesinurad with polyvinylpyrrolidones (PVP). More specifically, the present application relates to amorphous solid dispersion of lesinurad with PVP K-30 or HPMC.
  • PVP polyvinylpyrrolidones
  • silicon dioxide may be added to the amorphous solid dispersion of lesinurad, prepared by the process of this application, in order to increase the stability and to reduce the hygroscopicity of the amorphous solid dispersion.
  • Suitable techniques that may be used for the removal of solvent in step c) include but are not limited to rotational distillation using a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • a device such as Buchi Rotavapor, spray drying, agitated thin film drying (“ATFD”), freeze drying (lyophilization) and the like, optionally under reduced pressure.
  • step (d) may be same as used in step (a) or mixtures thereof
  • the blending may be carried out by known processes in the literature.
  • the processes which include but are not limited to physical blending, blending in rotatory equipment such as rotatory cone vacuum drier, mortar-pestle or similar suitable methods or combinations of any of these methods.
  • the isolation and purification can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, centrifugation, extraction, acid-base treatment, conventional isolation and refining means such as concentration, concentration under reduced pressure, solvent-extraction, crystallization, phase-transfer chromatography, column chromatography, or by a combination of these procedures.
  • suitable separation or purification procedure such as, for example, filtration, centrifugation, extraction, acid-base treatment, conventional isolation and refining means such as concentration, concentration under reduced pressure, solvent-extraction, crystallization, phase-transfer chromatography, column chromatography, or by a combination of these procedures.
  • the resulting solid may be collected by using techniques such as by scraping, or by shaking the container or other techniques specific to the equipment used.
  • the isolated solid may be optionally further dried to afford amorphous form of lesinurad.
  • the steps of the above embodiment may be performed at a temperature of about 0°C to about the boiling point of the solvent. Specifically, lesinurad may be dissolved in a suitable solvent at a temperature of about 0°C to about 1 10°C.
  • the present application relates to process for preparing amorphous solid dispersion of lesinurad comprising blending of lesinurad with one or more pharmaceutically acceptable excipients.
  • the blending may be carried out by known processes in the literature.
  • the processes which include but are not limited to physical blending, blending in rotatory equipment such as rotatory cone vacuum drier, mortar-pestle or similar suitable methods or combinations of any of these methods.
  • Any crystalline form or amorphous form of lesinurad or mixture thereof may be used as starting material for preparing amorphous form of lesinurad or amorphous solid dispersion of lesinurad.
  • Drying in all the embodiments discussed above of the present invention may be suitably carried out by using any of an air tray dryer, vacuum tray dryer, fluidized bed dryer, spin flash dryer, flash dryer, and the like.
  • the drying may be carried out at atmospheric pressure or above, or under reduced pressures, specifically at temperatures less than about 80 °C and more specifically less than about 60 °C.
  • the drying may be carried out for any time period required for obtaining a desired product quality, such as from about 30 minutes to about 24 hours, or longer.
  • the dried product in all the embodiments discussed above may optionally be subjected to a particle size reduction procedure to produce desired particle sizes and distributions. Milling or micronization may be performed before drying, or after the completion of drying of the product.
  • Equipment that may be used for particle size reduction includes but not limited to ball mill, roller mill, hammer mill, and jet mill.
  • the amorphous solid dispersion of lesinurad of the present invention is substantially free of any crystalline form of lesinurad.
  • Amorphous solid dispersion of lesinurad of the present invention does not contain more than about 10 % of any crystalline form of lesinurad.
  • amorphous solid dispersion of lesinurad does not contain more than about 5 % of any crystalline form of lesinurad.
  • amorphous solid dispersion of lesinurad does not contain more than about 1 % of any crystalline form of lesinurad.
  • the solid dispersion of amorphous form of lesinurad is stable and has excellent physico-chemical properties.
  • the solid dispersion of amorphous form of lesinurad of the present application may be easily formulated into a pharmaceutical composition along with suitable pharmaceutically acceptable excipients.
  • the present application provides pharmaceutical formulations comprising amorphous form of lesinurad, together with one or more pharmaceutically acceptable excipients, carrier and diluents.
  • the present application provides pharmaceutical composition comprising amorphous solid dispersion of lesinurad with a pharmaceutically acceptable excipient, together with one or more pharmaceutically acceptable excipients.
  • Amorphous lesinurad or solid dispersion of amorphous lesinurad together with one or more pharmaceutically acceptable excipients, carrier and diluents of the present application may be formulated as: solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as, but not limited to, syrups, suspensions, dispersions, and emulsions; and injectable preparations such as, but not limited to, solutions, dispersions, and freeze dried compositions.
  • Formulations may be in the forms of immediate release, delayed release, or modified release.
  • immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations; and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems.
  • the compositions may be prepared using any one or more of techniques such as direct blending, dry granulation, wet granulation, extrusion and spheronization.
  • Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated, and modified release coated.
  • the PXRD data reported herein are obtained using a PANalytical X-ray Diffractometer, with copper Ka radiation.
  • Syloid 250 mg was blended with Lesinurad (250 mg) at 30°C using a mortar pestle to afford the title compound.
  • Example 8 Preparation of amorphous solid dispersion of lesinurad

Abstract

La présente invention concerne une forme amorphe de lesinurad, une dispersion solide amorphe de lesinurad et leurs procédés de préparation. La présente invention concerne également une composition pharmaceutique comprenant une dispersion amorphe ou solide amorphe de lesinurad et un ou plusieurs excipients ou supports pharmaceutiquement acceptables.
PCT/IB2016/053605 2015-06-19 2016-06-17 Dispersions amorphes et solides amorphes de lesinurad et leur préparation WO2016203436A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3072CH2015 2015-06-19
IN3072/CHE/2015 2015-06-19
IN201641007907 2016-03-07
IN201641007907 2016-03-07

Publications (1)

Publication Number Publication Date
WO2016203436A1 true WO2016203436A1 (fr) 2016-12-22

Family

ID=57545071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053605 WO2016203436A1 (fr) 2015-06-19 2016-06-17 Dispersions amorphes et solides amorphes de lesinurad et leur préparation

Country Status (1)

Country Link
WO (1) WO2016203436A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3315494A1 (fr) * 2017-04-19 2018-05-02 Química Sintética, S.A. Forme amorphe de lésinurad et ses procédés de préparation
EP3498697A1 (fr) 2017-12-12 2019-06-19 Química Sintética, S.A. Nouveaux sels et polymorphes de lesinurad
CN111153862A (zh) * 2020-01-19 2020-05-15 北京鑫开元医药科技有限公司海南分公司 一种雷西纳德的精制方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197825A1 (en) * 2007-11-27 2009-08-06 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
WO2011159732A1 (fr) * 2010-06-15 2011-12-22 Ardea Biosciences,Inc. Traitement de la goutte et de l'hyperuricémie
US20120172405A1 (en) * 2010-12-30 2012-07-05 Ardea Biosciences Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
WO2015075561A2 (fr) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Formes cristallines de lésinurad et son sel de soude

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197825A1 (en) * 2007-11-27 2009-08-06 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
WO2011159732A1 (fr) * 2010-06-15 2011-12-22 Ardea Biosciences,Inc. Traitement de la goutte et de l'hyperuricémie
US20120172405A1 (en) * 2010-12-30 2012-07-05 Ardea Biosciences Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
WO2015075561A2 (fr) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Formes cristallines de lésinurad et son sel de soude

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3315494A1 (fr) * 2017-04-19 2018-05-02 Química Sintética, S.A. Forme amorphe de lésinurad et ses procédés de préparation
EP3498697A1 (fr) 2017-12-12 2019-06-19 Química Sintética, S.A. Nouveaux sels et polymorphes de lesinurad
CN111153862A (zh) * 2020-01-19 2020-05-15 北京鑫开元医药科技有限公司海南分公司 一种雷西纳德的精制方法
CN111153862B (zh) * 2020-01-19 2021-07-06 北京鑫开元医药科技有限公司海南分公司 一种雷西纳德的精制方法

Similar Documents

Publication Publication Date Title
US20220220123A1 (en) Amorphous and crystalline forms of relugolix
US20080014280A1 (en) Amorphous pregabalin and process for the preparation thereof
WO2018051280A1 (fr) Procédé de préparation de ribociclib, ses sels d'addition d'acides
WO2009114601A2 (fr) Préparation de lénalidomide
WO2010054056A2 (fr) Formes cristallines du chlorhydrate de nilotinib
CN110636845A (zh) 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体
WO2017037596A1 (fr) Dispersion solide amorphe de lcz-696
WO2016203436A1 (fr) Dispersions amorphes et solides amorphes de lesinurad et leur préparation
US20060111417A1 (en) Amorphous telmisartan
WO2018122780A1 (fr) Formes solides de mésylate de lenvatinib
WO2010129636A2 (fr) Lénalidomide polymorphe
US9045473B2 (en) Forms of Apixaban
WO2009084023A2 (fr) Rameltéon amorphe et son procédé de préparation
WO2017208169A1 (fr) Polymorphes de betrixaban et de son sel maléate
WO2012140632A1 (fr) Dispersion solide de fébuxostat
WO2018015974A1 (fr) Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
WO2013150544A2 (fr) Dispersion solide de chlorhydrate d'ivabradine
US20240082248A1 (en) Process for preparation of mavacamten and solid state forms thereof
CN117545755A (zh) 一种Lanifibranor的晶型及其制备方法
WO2016108123A2 (fr) Forme amorphe pure et dispersion solide amorphe de céritinib
WO2017115315A1 (fr) Formes solides de palbociclib
WO2018134843A1 (fr) Formes polymorphes de (e)-n-{4-[3-chloro-4-((pyridin-2-yl-méthoxy)-anilino]-3-cyano-7-éthoxyquinolin-6-yl)-4-(diméthylamino)-but-2-énamide, son sel de maléate et un procédé de préparation correspondant
US20080014263A1 (en) Amorphous eprosartan mesylate and process for the preparation thereof
US10206874B2 (en) Rufinamide solid dispersion
WO2021044350A1 (fr) Formes solides de mésylate d'encéquidar et procédés associés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16811124

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16811124

Country of ref document: EP

Kind code of ref document: A1